Synnovation Therapeutics Inc. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS), congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Synnovation Therapeutics Inc. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS).
Synnovation Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities).
Phosphatidylinositol 3-kinase α (PI3Kα) inhibitors have been reported in a Synnovation Therapeutics Inc. patent as useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
